Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome

Brooks Automation Shares Running Out Of Room To Run

Brooks Automation Shares Running Out Of Room To Run

Needham reassessed shares of Brooks Automation, Inc (NASDAQ: BRKS) Monday, downgrading the shares of the company because the stock price ran ahead of the firm's previous price target of $28.

As such, the firm downgraded the shares of the company from Buy to Hold.

At the time of writing, shares of Brooks Automation were, however, rising 1.30 percent to $28.90.

Sizeable Exposure To Low-Growth Semi Business

Analysts Edwin Mok and Arthur Su are of the view Brooks Automation management has succeeded in refocusing the semiconductor business into several growth areas such as etch/dep vacuum, CCs and AP. With half of the business not growing, as they focus on slower growing areas such as ATM, robots, cryopumps and service, Mok and Su believe the total semiconductor business will perform in line with the wafer fab equipment, or WFE market and underperform names with greater exposure to the technology inflections within SemiCap.

See also: Lam Research On The Cusp Of Healthy Chip Industry Environment; Argus Initiates At Buy

Life Science Growth Already Reflected In Model

Needham believes Brooks Automation's Life Science business is growing well, as recurring sales from avenues such as sample storage, infrastructure service and consumables increase. Taking cues from the backlog and the business momentum, the firm estimates that the business is on track to reach or even exceed the 2019 revenue target of $205 million, for a 2017-19 CAGR of 18 percent.

The firm expects recurring revenue to grow from about 60 percent of the total revenue. That said, the firm said the solid growth prospects of the Life Science business is already reflected in the Street's model. Additionally, the firm expects the lumpy tool business to moderate.

"We would wait for evidence of faster adoption of the new bio-sample tool to get more aggressive on the tool business," the firm said.

Valuation Has Factored In Updated FY19 Targets

Needham said the stock has already priced in the company's updated 2019 targets of revenues of $730 million to $815 million and NG earnings per share of $1.30–$1.80. Taking the mid-point of the earnings per share guidance, the firm estimates Life Sciences would contribute to 41 cents compared to $1.60 by Semi.

"The stock is currently trading at a 26% premium over its semi sub-system peers Advanced Energy Industries, Inc. (NASDAQ: AEIS) and MKS Instruments, Inc. (NASDAQ: MKSI) [N/R] on a P/ E basis, which we believe already reflects the benefit of the faster growing Life Science business," the firm added.

Needham also noted that its analysis suggested the Street is already assuming Brooks Automation will be able to accelerate its fiscal year 2019 target to calendar year 2018, or three quarters earlier than target.

Related Link: Applied Materials, Lam Research: Long Trade Ideas Heading Into Semicon West Trade Show

Latest Ratings for BRKS

Apr 2019MaintainsBuyBuy
Nov 2018MaintainsBuyBuy
Nov 2018MaintainsNeutralNeutral

View More Analyst Ratings for BRKS
View the Latest Analyst Ratings

Posted-In: Arthur Su Edwin MokAnalyst Color News Guidance Downgrades Analyst Ratings Tech Best of Benzinga


Related Articles (AEIS + BRKS)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Day Market Update: Dow Gains 75 Points; Nabriva Therapeutics Shares Spike Higher

Clovis Oncology Higher Off Unconfirmed Takeover Chatter